The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 06, 2007
Filed:
Apr. 02, 2003
Gary Mark Coppola, Budd Lake, NJ (US);
John William Davies, Winchester, MA (US);
Charles Francis Jewell, Jr., Sudbury, MA (US);
Yu-chin LI, Edison, NJ (US);
James Richard Wareing, Stow, MA (US);
Donald Mark Sperbeck, Berkeley Heights, NJ (US);
Travis Mathew Stams, Stow, MA (US);
Sidney Wolf Topiol, Fair Lawn, NJ (US);
Isidoros Vlattas, Summit, NJ (US);
Gary Mark Coppola, Budd Lake, NJ (US);
John William Davies, Winchester, MA (US);
Charles Francis Jewell, Jr., Sudbury, MA (US);
Yu-Chin Li, Edison, NJ (US);
James Richard Wareing, Stow, MA (US);
Donald Mark Sperbeck, Berkeley Heights, NJ (US);
Travis Mathew Stams, Stow, MA (US);
Sidney Wolf Topiol, Fair Lawn, NJ (US);
Isidoros Vlattas, Summit, NJ (US);
Novartis AG, Basel, CH;
Abstract
Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.